• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Therapy vs. Meds for ADHD: Lessons from the MTA Study

Therapy vs. Meds for ADHD: Lessons from the MTA Study

April 1, 2005
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Six short years ago, an influential study came out in Archives of General Psychiatry that was widely interpreted as showing that therapy adds little of value to the treatment of ADHD (Arch Gen Psychiatry 1999; 56:1073-1086). This was the “MTA Study,” (Multimodal Treatment study of children with ADHD) and it was seen as particularly legitimate because it was funded entirely by the NIMH. It was also the largest placebo-controlled study of stimulants ever published.

Children with ADHD (combined type) between the ages of 7 and 10 were recruited through six different sites, all of them academic centers. A total of 579 children were randomly assigned to one of four treatment groups: medication management, intensive behavioral treatment, combined medication and behavioral treatment, and standard community care (which generally included medication treatment).
Kids in the “medication-only” group received much more than a mere stimulant.

After 14 months of treatment, the kids were evaluated with standard assessment instruments. The results? Both the combined and medication groups fared better than the behavioral treatment and community care groups. There were no differences in ADHD symptoms between combined and medication. The question immediately arose: why provide expensive therapy to these kids at all, since combining intensive therapy with meds yielded no advantage over meds alone?

Well, the results were not so cut and dried.

While combined treatment did not do statistically better than meds alone, the kids in the combined group improved more in several non-ADHD symptom domains than kids in community care and therapy alone. These symptoms included oppositional/aggressive symptoms, internalizing symptoms, teacher-rated social skills, parent-child relations, and reading achievement; meds alone did not surpass the other groups in any of the non- ADHD symptom domains. In addition, kids in the combined group got by on lower doses of Ritalin (average 31.2 mg QD) than those in the medication group (37.7 mg). Thus, while therapy may do little for the core symptoms of ADHD, it helps mitigate problems that are equally troublesome in these kids, particularly oppositionality and poor relationships with parents and peers.

But there is yet another problem with the conclusion that this study endorses a “medication-only” approach to treating ADHD. One of the major, but underemphasized, results of the MTA study is that kids randomized to the medication group did significantly better than kids randomized to standard community care, most of whom also were prescribed medications. What accounted for this difference?

The difference was that the medication- only condition included a lot of extra care and monitoring than your typical ADHD kid receives in the doctor’s office. Here are the major elements of the MTA’s “medication-only” treatment protocol:

Clinicians prescribing medication were required, according to written algorithm, to continue titrating the dose of stimulants up to the point of optimal effectiveness.

  • Medication visits were monthly and lasted a full half-hour.

  • Clinicians provided “support, encouragement, and practical advice” without providing the behavioral therapy that was being tested in other arms of the study.

  • Parents were given readings about ADHD.

  • Each month, clinicians reviewed information on the child’s symptoms from both parents and teachers


I suspect that there aren’t many readers out there who schedule monthly half-hour medication visits for stimulant monitoring, who make sure to get teacher evaluations at every session, who give out special psychoeducational material to parents, and who use a research-driven algorithm to ensure the stimulant dose gets high enough, quickly enough. But one of the lessons of the MTA study is that we probably should be doing all these things if we want to get our patients well.

TCR VERDICT: Meds for core symptoms, therapy for all else
General Psychiatry
Carlat 150x150
Daniel Carlat, MD

20 Years of The Carlat Report

More from this author
www.thecarlatreport.com
Issue Date: April 1, 2005
SUBSCRIBE NOW
Table Of Contents
The Dark Side of Stimulants
Lawrence H. Diller, MD, on The Use of Stimulants in ADHD
Adderall and Death: It’s Team FDA versus Team Canada!
Therapy vs. Meds for ADHD: Lessons from the MTA Study
Psychostimulants and Strattera Explained
The Official TCR ADHD Medication Comparison Chart
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • KellieElvis2.jpeg
    General Psychiatry

    Elvis Presley and Pharmacokinetics - Part 2

    This common pharmacokinetic reaction will help you manage many of bad medication reactions in psychiatric practice. But did it lead to Elvis Presley’s death? 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.